Cardinal Health Nitrile Blue Examination Gloves Tested for Use with Chemotherapy Drugs and Fentanyl Citrate
Cardinalhealth · Decision date Sep 2, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 09/02/2026 for K261749, a traditional 510(k) submitted by Cardinalhealth of Waukegan, Illinois, and received 05/28/2026. The device is listed as Cardinal Health Nitrile Blue Examination Gloves Tested for Use with Chemotherapy Drugs and Fentanyl Citrate, under device classification name Polymer Patient Examination Glove, regulation number 880.6250, with primary product code LZA and subsequent codes LZC, OPJ and QDO. The review panel and regulation medical specialty are both General Hospital. SESE denotes clearance of the submission, not premarket approval.
The record shows the submission was not reviewed by a third party, is not a combination product, and has no authorized predetermined change control plan. The public page does not include the summary statement content, so the specific glove components, test methods, comparator devices and the basis for the chemotherapy-drug and fentanyl citrate testing claims remain unknown from this source. No clinical, efficacy or legal conclusion about the gloves is drawn here.
The page carries two differing last-updated dates, 10/26/2026 and 09/21/2026, and the source does not reconcile them.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General Hospital
- Decision date
- Sep 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261749
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Cardinalhealth
- Product code
- LZA
- Decision code
- SESE
- Decision date
- Sep 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Polymer Patient Examination Glove.
- Applicant
- Cardinalhealth
- Product code
- LZA
- FDA device class
- 1
FDA decision timeline
K261749 received
Application receipt date recorded by FDA.
K261749 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LZA
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Vietglove Corporation | 510(k) clearance | Oct 29, 2026 | FDA | |
| Yty Industry (Manjung) Sdn Bhd | 510(k) clearance | Oct 1, 2026 | FDA | |
| Maxter Healthcare, Inc. | 510(k) clearance | Sep 9, 2026 | FDA | |
| Top Glove Sdn. Bhd. | 510(k) clearance | Sep 9, 2026 | FDA | |
| Gmp Medicare Sdn. Bhd. | 510(k) clearance | Sep 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cardinalhealth
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Waukegan, IL
Sources and methodology
- Original FDA record: K261749
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records